Loading…
← CockpitCompetitor Analysis › INSM Insmed IncorporatedOpen in the cockpit ↗

Insmed IncorporatedINSMCompetitor analysis, valuation and peers

United States · USD·Health Care›Pharmaceuticals: Major

Biotech selling Arikayce for a rare lung infection and developing therapies for bronchiectasis and other rare respiratory diseases.

Momentum strong 74
Mkt cap
$26.3B
US dollars, full cap
Free float
99%
of shares outstanding
$/day
$401M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-161.0 pp
WACC 9.1%
Hurdle
n/a
no reverse DCF
Next earnings
99 days
25 Feb 2027
Close · USD$119.80
1D-1.7%
1W-0.8%
1M+25.2%
3M-4.2%
6M+3.3%
YTD-31.2%
1Y-36.9%
ATR %4.0%
Beta0.52
52w lowhigh43.7% off high

What Insmed does

Biotech selling Arikayce for a rare lung infection and developing therapies for bronchiectasis and other rare respiratory diseases.

Until 2025 earned all its revenue from Arikayce, an inhaled antibiotic for a rare lung infection, sold mainly in the US with some sales in Japan and Europe. Brensocatib, branded Brinsupri, was approved in the US in 2025 for bronchiectasis, a far bigger patient group, making it a company with a second product to launch. It is still loss-making.

Products and services

  • Arikayce (NTM lung disease)
  • Brensocatib (bronchiectasis)
  • Rare-disease pipeline

Customers

  • Pulmonologists
  • Rare-disease specialists
  • Payers

Where it sits in the supply chain

  • Pharmaceuticals
  • Biotech
  • Rare respiratory disease

What could go right

  • Brensocatib launch in bronchiectasis
  • Arikayce international expansion

What could go wrong

  • Small addressable patient populations
  • Execution risk on first non-Arikayce launch

Moat: narrow (IP / patents, regulatory licence). Orphan-drug exclusivity and specialist prescriber relationships in a very small patient population.

Headquarters: Bridgewater, New Jersey, United States · Founded: 1988 · Employees: 1,664

Named competitors

Insmed at a glance

Size Insmed (INSM) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $26.3B, the 411th largest of 3,085 United States companies the cockpit tracks. Shares closed at $119.80 on 18 Nov 2026.

Performance Over six months the shares gained 3.3%, against +10.7% for the median peer and -2.2% for the United States market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 240.0% over the last twelve months (peer median +20.1%); the operating margin is -41.7% (peer median 18.9%).

Valuation It trades at 17.0× enterprise value to sales against a peer median of 4.4× (4th most expensive of 21).

Capital Return on invested capital runs 161.0 points below its cost of capital (9.1% WACC).

Short interest Short interest is 6.4% of the free float (30 Oct 2026).

Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 110INSM 102
Six months, rebased to 100: Insmed against the median of its 20 peers (local-currency closes).

Insmed financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$1.52B$606M$364M$305M$245M
Revenue growth—+67%+19%+24%—
Gross profit$1.27B$477M$273M$235M$185M
EBITDA-$607M-$978M-$776M-$670M-$454M
Net income-$606M-$1.28B-$914M-$750M-$482M
Free cash flow-$658M-$998M-$706M-$550M-$410M
Capital expenditure$62.0M$62.6M$21.9M$13.3M$9.88M
Total debt$750M$756M$1.31B$1.36B$1.33B

Quarterly statements and history in the cockpit →

Insmed competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+10%+20%+30%+40%-10%0%+10%+20%3692ROIVINCYVTRSSIGDIVISLAB45684503ALNYZTS1801TORNTPHARMBIIB4507RPRXHLN4578ASNDEXELSDZINSM6-month return →1-month return →
Up and to the right = strong over both horizons. Insmed is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%10×20×3692ROIVINCYVTRSSIGDIVISLAB4568ALNYZTS1801TORNTPHARM4507RPRXHLNASNDEXELINSMRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Insmed is the large dot.

Insmed competitors and peer comparison

Head to head with its named competitors (INSM vs VRTX vs AZN.L)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Insmed INSM$26.3B+3%+240%-42%17.0×n/a
Vertex Pharmaceuticals VRTX$136B+25%+11%35%10.5×6.2%
AstraZeneca AZN.L$278B-2%+5%23%5.0×14.4%

How Insmed compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Insmed against its 20 peers (data as of 18 Nov 2026)
MeasureINSMPeer medianRank in peer set
1-month return+25.2%+4.5%highest of 21
6-month return+3.3%+10.7%6th lowest of 21
Distance from 52-week high-43.7%-9.1%2nd lowest of 21
Revenue growth (TTM)+240.0%+20.1%highest of 21
Operating margin-41.7%18.9%2nd lowest of 21
EV / Sales17.0×4.4×4th most expensive of 21
ROIC minus cost of capital-161.0 pp+5.4 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Insmed INSMUnited States$26.3B+3%+240%-42%17.0×n/an/a
Hansoh Pharma 3692.HKHong Kong$25.3B-3%+25%38%9.0×7.9%+10.8%
Roivant Sciences ROIVUnited States$28.1B+20%+102%-3,234%597.3×n/an/a
Incyte INCYUnited States$24.0B+21%+25%12%3.4×14.2%+14.0%
Viatris VTRSUnited States$23.3B+23%+5%11%2.4×11.2%+3.7%
Sigma Healthcare SIG.AXAustralia$22.4B+2%+209%9%3.3×28.9%+26.1%
Divi's Laboratories DIVISLAB.NSIndia$31.3B+60%+22%34%23.8×47.1%+8.9%
Daiichi Sankyo 4568.TJapan$31.4B+8%+17%13%2.1×7.6%+17.1%
Astellas Pharma 4503.TJapan$31.4B+17%+19%23%2.2×-9.0%+11.4%
Alnylam Pharmaceuticals ALNYUnited States$20.0B-50%+56%20%3.9×0.5%+49.8%
Zoetis ZTSUnited States$34.8B+7%+1%37%4.5×-2.9%+7.2%
Innovent Biologics 1801.HKHong Kong$18.9B+4%+43%17%7.3×11.6%+26.8%
Torrent Pharmaceuticals TORNTPHARM.NSIndia$18.8B+3%+42%22%10.7×37.6%+11.3%
Biogen BIIBUnited States$37.2B+34%+2%17%4.4×10.1%-5.1%
Shionogi & 4507.TJapan$17.6B+3%+46%29%4.9×0.2%+11.0%
Royalty Pharma RPRXUnited States$39.4B+29%+11%66%19.3×10.8%+2.3%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%3.4×5.2%+2.2%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%2.3×1.6%+11.7%
Ascendis Pharma A/S ASNDUnited States$16.9B+12%+94%18%11.7×19.2%+152.4%
Exelixis EXELUnited States$16.7B+37%+9%40%6.4×-3.8%+18.6%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%4.2×7.5%+0.4%

Questions

Who are Insmed's main competitors?
Named competitors: Vertex Pharmaceuticals (VRTX), AstraZeneca (AZN.L), Chiesi Group (private or unlisted). The cockpit's measured peer set (industry) also includes Hansoh Pharma (3692.HK), Roivant Sciences (ROIV), Incyte (INCY), Viatris (VTRS), Sigma Healthcare (SIG.AX), Divi's Laboratories (DIVISLAB.NS).
Is Insmed expensive compared with its peers?
On ev / sales it trades at 17.0× against a peer median of 4.4×, 4th most expensive of 21 in its peer set.
How has Insmed stock performed?
Over six months to 18 Nov 2026 the shares returned +3.3% against +10.7% for the median peer; over one year -36.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.